Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Humasys Co., Ltd. (205470:KRX), powered by AI.
Humasys Co., Ltd. is currently trading at ₩2,800. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Humasys Co., Ltd. on Alpha Lenz.
Humasys Co., Ltd.'s P/E ratio is -4.4.
“Humasys Co., Ltd. trades at a P/E of -4.4 (undervalued) with modest ROE of -7.0%.”
Ask for details →Humasys Co., Ltd. is a prominent player in the biotechnology sector, specializing in the development and commercialization of in-vitro diagnostic products. The company's primary focus lies in enhancing the accuracy and efficiency of diagnostic testing, catering to a wide array of medical and healthcare needs. Humasys offers a diverse range of products, including reagent kits and diagnostic devices that are pivotal for disease detection and management. Its innovative solutions are fundamental in clinical settings, research laboratories, and various healthcare institutions. Humasys significantly contributes to the medical community by providing cutting-edge diagnostic tools that facilitate early and accurate disease detection, improving patient outcomes. The company's products are an integral part of healthcare delivery, playing a crucial role in preventive medicine and routine health screenings. As healthcare systems globally strive for improved diagnostic capabilities, Humasys stands out as a key contributor to the sector's advancements. By bridging the gap between advanced biotechnology and practical healthcare applications, Humasys Co., Ltd. holds a vital position in the financial market, reflecting the ongoing importance of reliable medical diagnostics in society.
“Humasys Co., Ltd. trades at a P/E of -4.4 (undervalued) with modest ROE of -7.0%.”
Ask for details →Humasys Co., Ltd. (ticker: 205470) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 70 employees. Market cap is $69.1B.
The current price is ₩2,800 with a P/E ratio of -4.42x and P/B of 0.32x.
ROE is -7.03% and operating margin is -46.64%. Annual revenue is $30.1B.